European Journal of Epidemiology

, Volume 27, Issue 11, pp 857–866 | Cite as

Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study

  • Paraskevi Panagopoulou
  • Helen Gogas
  • Nick Dessypris
  • Nikos Maniadakis
  • George Fountzilas
  • Eleni Th. Petridou
CANCER

Abstract

Apart from tumour, treatment and patient characteristics at diagnosis, access to healthcare delivery may as well play a significant role in breast cancer prognosis. This study aimed to assess the additional impact exerted on survival by travel burden—a surrogate indicator of limited access to healthcare- expressed as geographical distance and/or time needed to reach the tertiary healthcare center from the patient’s residence. Between 1997 and 2005, 2,789 women participated in therapeutic clinical trials conducted by the Hellenic Cooperative Oncology Group. The effect of geographical distance and travel time between patient’s residence and treating hospital on survival was estimated using Cox proportional hazards regression adjusting for age, menopausal status, tumour size/grade, positive nodes (number), hormonal receptor status, HER2 overexpression, surgery type/treatment protocol as well as for body mass index >30 kg/m2. More aggressive tumour features, older treatment protocols and modifiable patient characteristics, such as obesity (HR: 1.27) adversely impacted on breast cancer survival. In addition, less studied indicators of access to healthcare, such as geographic distance >350 km and travel time >4 h were independently and significantly associated with worse outcomes (HR = 1.43 and 1.34 respectively). In conclusion, to address inequalities in breast cancer survival, improvements in access to healthcare services related to increased travel burden especially for patients of lower socioeconomic status should be considered, more than ever at times of financial crisis and independently of already known modifiable patient characteristics.

Keywords

Breast cancer Survival Prognosis Healthcare access Healthcare inequalities Obesity Socioeconomic status (SES) 

Notes

Ethical standards

The present study complies with the current laws of the Greece.

Conflict of interest

All authors declare that they have no conflict of interest.

Supplementary material

10654_2012_9737_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 14 kb)

References

  1. 1.
    Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106. doi: 10.1016/S0140-6736(05)67887-7.PubMedGoogle Scholar
  3. 3.
    Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245–62. doi: 10.1677/erc-10-0136.PubMedCrossRefGoogle Scholar
  4. 4.
    Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol. 2006;17(10):1504–11. doi: 10.1093/annonc/mdl147.PubMedCrossRefGoogle Scholar
  5. 5.
    Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008;123(9):2188–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Hellmann SS, Thygesen LC, Tolstrup JS, Gronbaek M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. Eur J Cancer Prevent. 2010;19(5):366–73. doi: 10.1097/CEJ.0b013e32833b4828.CrossRefGoogle Scholar
  7. 7.
    Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, et al. Greater Survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25(17):2345–51. doi: 10.1200/jco.2006.08.6819.PubMedCrossRefGoogle Scholar
  8. 8.
    Parkin DM, Boyd L. Cancers attributable to overweight and obesity in the UK in 2010. Br J Cancer. 2011;105(S2):S34–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Protani M, Coory M, Martin J. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15(6):875–84. doi: 10.1093/annonc/mdh222.PubMedCrossRefGoogle Scholar
  11. 11.
    Barnett GC, Shah M, Redman K, Easton DF, Ponder BAJ, Pharoah PDP. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol. 2008;26(20):3310–6. doi: 10.1200/jco.2006.10.3168.PubMedCrossRefGoogle Scholar
  12. 12.
    Ewertz M, Jensen M-B, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2010;29(1):25–31. doi: 10.1200/jco.2010.29.7614.PubMedCrossRefGoogle Scholar
  13. 13.
    Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1871–7. doi: 10.1158/1055-9965.epi-06-0356.PubMedCrossRefGoogle Scholar
  14. 14.
    Dignam JJ, Mamounas EP. Obesity and breast cancer prognosis: an expanding body of evidence. Ann Oncol. 2004;15(6):850–1. doi: 10.1093/annonc/mdh241.PubMedCrossRefGoogle Scholar
  15. 15.
    Bouchardy C, Verkooijen HM, Fioretta G. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer. 2006;119(5):1145–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Dalton SO, Ross L, Düring M, Carlsen K, Mortensen PB, Lynch J, et al. Influence of socioeconomic factors on survival after breast cancer—a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999. Int J Cancer. 2007;121(11):2524–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94(7):490–6. doi: 10.1093/jnci/94.7.490.PubMedCrossRefGoogle Scholar
  18. 18.
    Yu X. Socioeconomic disparities in breast cancer survival: relation to stage at diagnosis, treatment and race. BMC Cancer. 2009;9(1):364.PubMedCrossRefGoogle Scholar
  19. 19.
    McGinnis JM, Williams-Russo P, Knickman JR. The case for more active policy attention to health promotion. Health Aff. 2002;21(2):78–93. doi: 10.1377/hlthaff.21.2.78.CrossRefGoogle Scholar
  20. 20.
    Probst J, Laditka S, Wang J-Y, Johnson A. Effects of residence and race on burden of travel for care: cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Services Res. 2007;7(1):40.CrossRefGoogle Scholar
  21. 21.
    Zgibor JC, Gieraltowski LB, Talbott EO, Fabio A, Sharma RK, Karimi H. The association between driving distance and glycemic control in rural areas. J Diabetes Sci Technol. 2011;5(3):494–500.PubMedGoogle Scholar
  22. 22.
    Scoggins JF, Fedorenko CR, Donahue SMA, Buchwald D, Blough DK, Ramsey SD. Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health. 2011; Article first published online: 31 Mar 2011. doi: 10.1111/j.1748-0361.2011.00371.x.
  23. 23.
    Dejardin O, Remontet L, Bouvier AM, Danzon A, Tretarre B, Delafosse P, et al. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. Br J Cancer. 2006;95(7):944–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Crawford SM, Sauerzapf V, Haynes R, Zhao H, Forman D, Jones AP. Social and geographical factors affecting access to treatment of lung cancer. Br J Cancer. 2009;101(6):897–901.PubMedCrossRefGoogle Scholar
  25. 25.
    Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92(3):269–71. doi: 10.1093/jnci/92.3.269.PubMedCrossRefGoogle Scholar
  26. 26.
    Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer. 2008;44(7):992–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Baird G, Flynn R, Baxter G, Donnelly M, Lawrence J. Travel time and cancer care: an example of the inverse care law? Rural Remote Health. 2008;8(4):1003 (Online). Epub Nov 13, 2008.Google Scholar
  28. 28.
    Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16(11):1762–71. doi: 10.1093/annonc/mdi366.PubMedCrossRefGoogle Scholar
  29. 29.
    Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19(5):853–60. doi: 10.1093/annonc/mdm539.PubMedCrossRefGoogle Scholar
  30. 30.
    Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat. 2011;2011 Dec 21. [Epub ahead of print] doi: 10.1007/s10549-011-1913-4.
  31. 31.
    Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and Weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) Study. Cancer Invest. 2008;26(5):491–8. doi: 10.1080/07357900701829785.PubMedCrossRefGoogle Scholar
  32. 32.
    Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papakostas P, et al. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol. 2006;23(4):479–88.PubMedCrossRefGoogle Scholar
  33. 33.
    Acock AC. Working with missing values. J Marriage Fam. 2005;67:1012–28.CrossRefGoogle Scholar
  34. 34.
    Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley; 1987.Google Scholar
  35. 35.
    Meden T, St. John-Larkin C, Hermes D, Sommerschield S. Relationship between travel distance and utilization of breast cancer treatment in rural northern michigan. JAMA. 2002;287(1):111. doi: 10.1001/jama.287.1.111.PubMedCrossRefGoogle Scholar
  36. 36.
    Celaya M, Rees J, Gibson J, Riddle B, Greenberg E. Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control. 2006;17(6):851–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Ahamad A. Geographic access to cancer care: a disparity and a solution. Postgrad Med J. 2011;87(1031):585–9. doi: 10.1136/pgmj.2010.111930.PubMedCrossRefGoogle Scholar
  38. 38.
    Wan Y. Examine the effect of geographic distance on breast cancer patients’ utilization of high volume hospitals [Master of Science Thesis]. Iowa. University of Iowa; 2009. http://ir.uiowa.edu/etd/446.
  39. 39.
    Wee C, McCarthy E, Davis R, Phillips R. Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med. 2000;132(9):697–704.PubMedGoogle Scholar
  40. 40.
    Mitchell KJ, Fritschi L, Reid A, McEvoy SP, Ingram DM, Jamrozik K, et al. Rural-urban differences in the presentation, management and survival of breast cancer in Western Australia. Breast. 2006;15(6):769–76. doi: 10.1016/j.breast.2006.04.001.PubMedCrossRefGoogle Scholar
  41. 41.
    Gulliford M, Figueroa-Munoz J, Morgan M, Hughes D, Gibson B, Beech R, et al. What does ‘access to health care’ mean? J Health Serv Res Policy. 2002;7(3):186–8. doi: 10.1258/135581902760082517.PubMedCrossRefGoogle Scholar
  42. 42.
    OECD. Regions at a glance 2007. Regional disparities in GDP per capita. 2007. p. 58–3. Available from: www.sourceoecd.org/governance/9789264009875.
  43. 43.
    Charalampopoulou A, Petridou E, Spyridopoulos T, Dessypris N, Oikonomou A, Athanasiadou-Piperopoulou F, et al. An integrated evaluation of socioeconomic and clinical factors in the survival from childhood acute lymphoblastic leukaemia: a study in Greece. Eur J Cancer Prev. 2004;13(5):397–401.PubMedCrossRefGoogle Scholar
  44. 44.
    Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.PubMedGoogle Scholar
  45. 45.
    Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18(6):883–93. doi: 10.1089/jwh.2008.1127.CrossRefGoogle Scholar
  46. 46.
    Loi S, Milne RL, Friedlander ML, McCredie MRE, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1686–91. doi: 10.1158/1055-9965.epi-05-0042.PubMedCrossRefGoogle Scholar
  47. 47.
    Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, et al. Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158(10):963–8. doi: 10.1093/aje/kwg236.PubMedCrossRefGoogle Scholar
  48. 48.
    Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13(4):325–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Hall HI, Coates RJ, Uhler RJ, Brinton LA, Gammon MD, Brogan D, et al. Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer. 1999;82(1):23–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267–73. doi: 10.1001/archinte.165.11.1267.PubMedCrossRefGoogle Scholar
  51. 51.
    McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003;21(10):1961–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Maehle B, Tretli S. Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat. 1996;41(2):123–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T, et al. editors [S2-1]. Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer. 33rd Annual San Antonio Breast Cancer Symposium; 2010; San Antonio, Texas, USA.Google Scholar
  54. 54.
    Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011;117(18):4132–40.PubMedCrossRefGoogle Scholar
  55. 55.
    Parolin V, Fiorio E, Mercanti A, Riolfi M, Cetto GL, Surmacz E, et al. Impact of BMI on clinical outcome of HER2-positive breast cancer. J Clin Oncol. 2010;28:15s(suppl;abstr 1130).Google Scholar
  56. 56.
    Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol. 2008;26(6):833–4. doi: 10.1200/jco.2007.14.7132.PubMedCrossRefGoogle Scholar
  57. 57.
    Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-i, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48–60. doi: 10.1093/jnci/djn415.PubMedCrossRefGoogle Scholar
  58. 58.
    Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler D. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 2011;378(9801):1457–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Paraskevi Panagopoulou
    • 1
  • Helen Gogas
    • 2
  • Nick Dessypris
    • 1
  • Nikos Maniadakis
    • 3
  • George Fountzilas
    • 4
  • Eleni Th. Petridou
    • 1
  1. 1.Department of Hygiene, Epidemiology and Medical StatisticsAthens University Medical SchoolAthensGreece
  2. 2.1st Department of Medicine, “Laiko” General HospitalUniversity of AthensAthensGreece
  3. 3.Department of Health Services Organisation and ManagementNational School of Public HealthAthensGreece
  4. 4.Department of Medical Oncology, “Papageorgiou” General HospitalAristotle University of Thessaloniki School of MedicineThessalonikiGreece

Personalised recommendations